Focused Investors LLC Has Raised Position in Johnson & Johnson (JNJ)

September 16, 2018 - By Jenna Rose

Johnson & Johnson (NYSE:JNJ) LogoInvestors sentiment increased to 0.97 in Q2 2018. Its up 0.04, from 0.93 in 2018Q1. It increased, as 36 investors sold JNJ shares while 806 reduced holdings. 114 funds opened positions while 704 raised stakes. 1.84 billion shares or 8.07% more from 1.71 billion shares in 2018Q1 were reported. Tru Com Of Oklahoma holds 0% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 6,003 shares. Salem Inv Counselors owns 161,250 shares for 1.79% of their portfolio. Aspiriant Ltd Company holds 46,768 shares. Dana Inv has 1.43% invested in Johnson & Johnson (NYSE:JNJ) for 269,349 shares. Uss Inv Mngmt Limited owns 0.15% invested in Johnson & Johnson (NYSE:JNJ) for 114,407 shares. 116,167 were accumulated by Schaper Benz & Wise Inv Counsel Wi. Salient Trust Com Lta reported 2.4% of its portfolio in Johnson & Johnson (NYSE:JNJ). Cambridge Trust reported 295,671 shares. State Bank Of Nova Scotia has invested 0.46% in Johnson & Johnson (NYSE:JNJ). Mackenzie Fincl has invested 1.27% of its portfolio in Johnson & Johnson (NYSE:JNJ). Laffer Investments holds 0% or 5,501 shares in its portfolio. 1.46 million are held by Mawer Invest Mngmt Limited. Moreover, Stratos Wealth Prtnrs has 0.75% invested in Johnson & Johnson (NYSE:JNJ) for 138,625 shares. Bradley Foster Sargent Ct accumulated 430,162 shares or 1.87% of the stock. Addison Capital reported 46,729 shares.

Since August 27, 2018, it had 0 buys, and 2 selling transactions for $4.99 million activity. Sneed Michael E sold $3.91 million worth of Johnson & Johnson (NYSE:JNJ) on Monday, August 27.

Focused Investors Llc increased its stake in Johnson & Johnson (JNJ) by 6.09% based on its latest 2018Q2 regulatory filing with the SEC. Focused Investors Llc bought 69,200 shares as the company’s stock rose 13.64% with the market. The institutional investor held 1.21 million shares of the major pharmaceuticals company at the end of 2018Q2, valued at $146.37M, up from 1.14 million at the end of the previous reported quarter. Focused Investors Llc who had been investing in Johnson & Johnson for a number of months, seems to be bullish on the $374.22B market cap company. The stock decreased 0.29% or $0.4 during the last trading session, reaching $139.49. About 4.53M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 5.07% since September 16, 2017 and is uptrending. It has underperformed by 10.55% the S&P500.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Seekingalpha.com which released: “Johnson & Johnson (JNJ) Management Presents at Barclays Global Consumer Staples Conference Call (Transcript)” on September 06, 2018, also Seekingalpha.com with their article: “Breakout Alert: Buy Johnson & Johnson” published on August 20, 2018, Seekingalpha.com published: “J&J working on India hip compensation” on September 07, 2018. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Johnson & Johnson (JNJ) CEO Alex Gorsky Presents at 2018 Wells Fargo 13th Annual Healthcare Conference …” published on September 06, 2018 as well as Seekingalpha.com‘s news article titled: “Johnson & Johnson (JNJ) Pharmaceutical Business Review Conference (Transcript)” with publication date: September 13, 2018.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 9 analysts covering Johnson & Johnson (NYSE:JNJ), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Johnson & Johnson had 13 analyst reports since March 23, 2018 according to SRatingsIntel. The stock has “Buy” rating by Credit Suisse on Tuesday, June 12. The company was upgraded on Thursday, July 12 by Goldman Sachs. As per Friday, April 20, the company rating was maintained by Credit Suisse. Wells Fargo maintained the shares of JNJ in report on Wednesday, April 18 with “Buy” rating. The firm earned “Buy” rating on Thursday, May 17 by Leerink Swann. Stifel Nicolaus maintained the stock with “Hold” rating in Wednesday, April 18 report. The stock of Johnson & Johnson (NYSE:JNJ) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, April 10. Deutsche Bank maintained Johnson & Johnson (NYSE:JNJ) on Wednesday, April 18 with “Buy” rating. The stock has “Buy” rating by Jefferies on Friday, April 13. Credit Suisse upgraded Johnson & Johnson (NYSE:JNJ) on Thursday, April 12 to “Buy” rating.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.